NUWE vs. CODX, LFWD, NRXS, PTHL, BSGM, NEPH, PETV, LYRA, ALUR, and BLAC
Should you be buying Nuwellis stock or one of its competitors? The main competitors of Nuwellis include Co-Diagnostics (CODX), ReWalk Robotics (LFWD), NeurAxis (NRXS), Pheton Holdings Ltd Class A Ordinary Shares (PTHL), BioSig Technologies (BSGM), Nephros (NEPH), PetVivo (PETV), Lyra Therapeutics (LYRA), Allurion Technologies (ALUR), and Bellevue Life Sciences Acquisition (BLAC). These companies are all part of the "medical equipment" industry.
Nuwellis vs.
Co-Diagnostics (NASDAQ:CODX) and Nuwellis (NASDAQ:NUWE) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, media sentiment, profitability, dividends, risk, analyst recommendations and community ranking.
Co-Diagnostics currently has a consensus target price of $1.50, suggesting a potential upside of 112.77%. Nuwellis has a consensus target price of $17.00, suggesting a potential upside of 1,207.69%. Given Nuwellis' stronger consensus rating and higher probable upside, analysts clearly believe Nuwellis is more favorable than Co-Diagnostics.
Nuwellis has higher revenue and earnings than Co-Diagnostics. Co-Diagnostics is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks.
In the previous week, Co-Diagnostics and Co-Diagnostics both had 3 articles in the media. Co-Diagnostics' average media sentiment score of 0.00 equaled Nuwellis'average media sentiment score.
15.0% of Co-Diagnostics shares are owned by institutional investors. Comparatively, 3.1% of Nuwellis shares are owned by institutional investors. 6.1% of Co-Diagnostics shares are owned by company insiders. Comparatively, 2.6% of Nuwellis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Co-Diagnostics received 251 more outperform votes than Nuwellis when rated by MarketBeat users. Likewise, 62.90% of users gave Co-Diagnostics an outperform vote while only 53.66% of users gave Nuwellis an outperform vote.
Co-Diagnostics has a beta of -0.63, suggesting that its stock price is 163% less volatile than the S&P 500. Comparatively, Nuwellis has a beta of 0.31, suggesting that its stock price is 69% less volatile than the S&P 500.
Nuwellis has a net margin of -169.54% compared to Co-Diagnostics' net margin of -563.93%. Co-Diagnostics' return on equity of -54.94% beat Nuwellis' return on equity.
Summary
Nuwellis beats Co-Diagnostics on 9 of the 17 factors compared between the two stocks.
Get Nuwellis News Delivered to You Automatically
Sign up to receive the latest news and ratings for NUWE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nuwellis Competitors List
Related Companies and Tools
This page (NASDAQ:NUWE) was last updated on 2/22/2025 by MarketBeat.com Staff
